Weight
CJC-1295 (without DAC)
Growth
29
Amino acids
Molecular weight
Peptide
Type
Synthetic growth hormone releasing hormone analog with short half-life enabling pulsatile GH secretion patterns resembling natural physiology. Unlike CJC-1295 with DAC, this version preserves natural GH pulsatility without continuous elevation.
Top researched benefits
Overview of CJC-1295 (without DAC)
Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.
Growth Hormone
- Restores natural GH pulsatility patterns in aging individuals.
- Elevates IGF-1 through enhanced GH secretion.
- Supports pituitary axis without suppression of natural function.
Antiaging
- Supports maintenance of lean muscle mass through GH elevation.
- Supports bone health through GH-mediated pathways.
- Improvements in skin quality through collagen synthesis.
Recovery
- Enhanced recovery from training through GH elevation.
- Improved sleep architecture with bedtime dosing.
Storage
Lyophilized: 2-8°C refrigerated; Reconstituted: 2-8°C refrigerated, use within 30 days
Frequency
2-3 times daily (morning, post-workout optional, bedtime)
Typical Dose
100-300mcg per injection
Cycle Duration
12-16 weeks
Chemical Makeup
Key benefits
Preserves natural GH pulsatility
Minimal side effects
No receptor desensitization
Precise GH release control
4x greater receptor affinity than native GHRH
Community interest
This peptide is still gaining traction in the community.
Short-Acting Growth Hormone Releasing Hormone Analog
This overview is informational and based on aggregated descriptions from studies and user reports.
Was it helpful?YesCJC-1295 (without DAC) Molecular Information
View the scientifc details of CJC-1295 (without DAC).
29
Amino Acids
CJC-1295 (without DAC)
Tyr
Tyr
Position 1
Ala
Ala
Position 2
Asp
Asp
Position 3
Ala
Ala
Position 4
?
?
Position 5
Phe
Phe
Position 6
?
?
Position 7
Gln
Gln
Position 8
Ser
Ser
Position 9
Tyr
Tyr
Position 10
Arg
Arg
Position 11
Lys
Lys
Position 12
Val
Val
Position 13
Leu
Leu
Position 14
Ala
Ala
Position 15
Gln
Gln
Position 16
Leu
Leu
Position 17
Ser
Ser
Position 18
Ala
Ala
Position 19
Arg
Arg
Position 20
Lys
Lys
Position 21
Leu
Leu
Position 22
Leu
Leu
Position 23
Gln
Gln
Position 24
Asp
Asp
Position 25
?
?
Position 26
Leu
Leu
Position 27
Ser
Ser
Position 28
Arg
Arg
Position 29
Molecular Weight
3367.9DaChain Length
29Amino AcidsType
PeptideCJC-1295 (without DAC) Protocols
Subcutaneous injection is the only effective route. Best administered on empty stomach, 30+ minutes away from food.
| Goal | Dosage | Frequency | Route |
|---|---|---|---|
| Anti-Aging/Wellness | 100 | 2 week range | SubQ |
| Body Composition | 100 | 3 week range | SubQ |
| Maximum GH Release | 200 | 2 week range | SubQ |
| Sleep Enhancement | 100 | 1 week range | SubQ |
Reconstitution Instructions
Materials needed:
Steps to reconstitute
- Clean vial tops with alcohol pad and allow to dry
- Draw bacteriostatic water slowly
- Inject water along vial side
- Gently roll to mix—avoid vigorous shaking
- Verify solution clarity; cloudiness indicates degradation
- Label with date and concentration
- Refrigerate immediately, use within 30 days
CJC-1295 (without DAC) Cycle
The CJC-1295 (without DAC) Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.
Taking breaks between cycles may help maintain effectiveness and support better overall results.
- Day 1-7
- Improved sleep quality; vivid dreams from enhanced REM
- Week 2-4
- Enhanced workout recovery, reduced muscle soreness, better pumps
- Week 4-8
- Noticeable skin improvements, minor body composition shifts
- Week 8-12
- Significant lean gains, fat loss, improved joint comfort
- Week 0-0
- Continued gradual improvements in composition and well-being
Dosing tools
CJC-1295 (without DAC) Peptide Dosage Calculator
Calculate peptide doses with our visual syringe guide.
0.3mL / 30 units
5 units
0.050 mL
1 mL
2 mL
3 mL
5 mL
Custom
Conversion: 1,000 mcg = 1 mg
Injection Results
Based on your vial and dilution inputs.
Safe concentration range
CJC-1295 (without DAC)
SINGLE COMPOUNDVolume per injection
0.05
mL
Concentration
10.00
mg/mL
Doses per vial
20
doses
Total injections per vial
20 injections
How it works
Based on a 10 mg CJC-1295 (without DAC) vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.
Research Purposes Only
These calculators are provided for educational and research purposes only. Always verify calculations and consult with qualified professionals. The information provided is not medical advice. Peptides should only be used in accordance with applicable laws and regulations.
Reference Guide
Dosing Cycle
- Peptide
- CJC-1295 (without DAC)
- Dosing
- 100-300mcg per injection
- Dosing Frequency
- 2-3 times daily (morning, post-workout optional, bedtime)
- Cycle Duration
- 12-16 weeks
- Storage
- Lyophilized: 2-8°C refrigerated; Reconstituted: 2-8°C refrigerated, use within 30 days
Note: Triple agonist; microdose for fewer side effects
Reconstitution Tips
- Use bacteriostatic water (BAC) — contains 0.9% benzyl alcohol for preservation
- Inject water slowly — aim down the vial wall, not directly onto powder
- Never shake — gently swirl or roll the vial until dissolved
- Store properly — refrigerate at 2-8°C after reconstitution
- Use within 28 days — most reconstituted peptides remain stable for about 4 weeks
- Keep sterile — always clean vial tops with alcohol before drawing
Peptide Interactions
Research suggestions of CJC-1295 (without DAC) interactions with other common peptides and substances.
Weight
ipa
Growth
Ipamorelin
SYNERGISTIC
Complementary GH release via different receptor pathways. Popular combination.
Weight
mk6
Growth
MK-677
COMPATIBLE
Different mechanisms; continuous ghrelin versus pulsatile GHRH.
Weight
tesa
Growth
Tesamorelin
MONITOR
Both are GHRH analogs; combining offers no additional benefit.
Side effects
Avoid: Do not take CJC-1295 (without DAC) with CJC-1295 with DAC.
Monitor: Be careful when combining CJC-1295 (without DAC) with Hexarelin, Tesamorelin.
Contraindications
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Stop signs
Persistent joint pain or carpal tunnel symptoms
Significant water retention or edema
Unexplained headaches or vision changes
Extreme fatigue or lethargy
Allergic reaction signs at injection sites
Bad signs
Comments
0.0
0 reviews
5
4
3
2
1
No comments yet
Be the first to share your experience. Your review helps others make more informed decisions.
Frequently asked questions
What benefits can peptides offer in research?
Peptides can support cellular repair, immune function, metabolic health, and tissue regeneration. Research suggests they may help with recovery, sleep quality, skin health, and cognitive function, depending on the specific peptide and its mechanism of action.
What are some exciting applications of peptides in modern science?
Current research explores peptides for longevity, muscle recovery, wound healing, metabolic disorders, and neuroprotection. Scientists are also investigating peptide-based drug delivery and targeted therapies that could offer more precise treatment options.
How do peptides influence health and wellness?
Peptides work by binding to receptors on cells and triggering specific biological responses. Depending on the peptide, they may promote growth hormone release, support collagen production, modulate inflammation, or influence neurotransmitter activity—each with different implications for health and wellness.
Where can I find the latest studies on peptide applications?
Peer-reviewed journals such as Nature, Science, and specialized publications like Peptides and the Journal of Peptide Science publish ongoing research. PubMed and Google Scholar are useful for searching studies by peptide name or condition.
Are there any guidelines for using peptides in research?
Research use of peptides typically follows institutional review board (IRB) protocols and regulatory guidelines. Dosage, administration route, and safety monitoring should align with published literature and applicable regulations in your jurisdiction.
What is the difference between peptides and proteins?
Peptides are short chains of amino acids (typically under 50), while proteins are longer chains that fold into complex structures. Peptides are often more stable, easier to synthesize, and can cross cell membranes more readily, making them attractive for therapeutic applications.
How should peptides be stored?
Most peptides require refrigeration (2–8°C) and protection from light. Reconstituted peptides often have shorter stability and may need to be used within days or weeks. Always follow the manufacturer's or research protocol's storage instructions.
Can peptides be taken orally?
Some peptides are bioavailable orally, but many are broken down by digestive enzymes before reaching the bloodstream. Subcutaneous injection, nasal administration, or other routes are often used in research to improve bioavailability. The optimal route depends on the specific peptide.
CJC-1295 (without DAC)Research References
CJC-1295 (without DAC) is a well studied compound
CJC-1295 (without DAC)
CJC-1295 (without DAC) is a well studied compound
Pharmacokinetics of Modified GRF(1-29) in Healthy Adults
Human study with 100-200mcg single dose in 12 subjects showed rapid absorption with peak GH at 15-30 minutes; established half-life and optimal frequency.
2006
Growth Hormone Pulsatility with Mod GRF 1-29
Human study with 100mcg 3x daily for 30 days in 24 subjects preserved natural GH pulsatility patterns with no pituitary desensitization.
2008
Comparative Analysis: CJC-1295 vs Native GHRH
In vitro and human receptor binding assays showed 4x greater receptor affinity than native GHRH with enhanced enzymatic degradation resistance.
2010
Long-term Safety Profile of Modified GRF Analogs
Animal model with 6 months daily administration showed no significant pituitary morphology or function changes supporting chronic safety.
2015